加兰他敏与吡拉西坦治疗老年性痴呆和良性衰老性遗忘症的比较

目的：评估加兰他敏胶囊治疗老年性痴呆和单纯性记忆障碍的疗效。方法：４２ 例老年性痴呆和３２ 例单纯性记忆障碍病人入组,其中３７ 例（ 男性２２例,女性１５ 例,年龄６３ ａ ±ｓ ８ ａ） 用加兰他敏胶囊１０ ｍ ｇ ,ｐｏ ,ｑｉｄ ,另３７ 例（ 男性２２ 例,女性１５ 例,年龄６５ ａ ±７ ａ） 用吡拉西坦胶囊８００ ｍ ｇ ,ｐｏ ,ｔｉｄ ,疗程均为８ ｗ ｋ 。结果：加兰他敏组总有效率７０ ％ ,吡拉西坦组为４０ ％ （ Ｐ＜ ０ ．０１） ,加兰他敏组痴呆病人日 常生活功能也较治疗前有明显提高（ Ｐ＜ ０ ．０１） ,该药不良反应轻。结论：加兰他敏胶囊治疗老年性痴呆安全有效。     

茴拉西坦改善老年痴呆性记忆障碍

目的：观察单一口服茴拉西坦治疗血管性痴呆的记忆障碍的疗效。方法：随机选择２７名病人,男性２１例,女性６例,年龄６４±ｓ７ａ（５０～７９ａ）,病程４±３ａ（６ｍｏ～１０ａ）,每天服用茴拉西坦０．６ｇ,共服用８ｗｋ。结果：服药后记忆商较服药前有不同程度的提高（Ｐ＜０．０５）。结论：茴拉西坦对血管性痴呆的记忆障碍有一定的改善作用。     

石杉碱甲片治疗阿耳茨海默病的临床疗效

目的；观察石杉碱甲片治疗阿耳茨海默病（ＡＤ）临床疗效。方法：选择符合ＩＣＤ－１０诊断标准的４１例ＡＤ患者，随机给其中治疗组（２３例）投用石杉碱甲０．１５ｍｇｂｉｄ对照组（１８例）投用砒啦西坦１．２ｇｂｉｄ，８ｗｋ为一疗程，疗前，疗后分别进行韦工记忆量表（ＷＭＳ）和简明智力量表（ＭＭＳＥ）的检测和评分比较，结果：两组治疗前，后ＷＭＳ的记忆商（ＭＱ）和ＭＭＳＥ总评分，自身比较有显著性差异（治疗组Ｐ〈０     

氢麦角碱治疗老年性痴呆

选择65yr以上轻至中度老年性痴呆20例,口服氢麦角碱(HDG)3-4mg/d,治疗8wk。有效率为85％;平均生效时间3.2±1.6 wk。治疗前后测定MMSE和SCAG亦示85％病例有效;SCAG的18个靶症状几乎都有改善。结论认为HDG对病情尚未严重的老年性痴呆有良好疗效,有认知障碍的老年患者应尽早仔细检查各种可能的原因,早期给予HDG可以争取较好的治疗效果。     

Protective effects of Nicotiflorin on reducing memory dysfunction, energy metabolism failure and oxidative stress in multi-infarct dementia model rats

The present study aimed to determine whether Nicotiflorin, a natural flavonoid extracted from coronal of Carthamus tinctorius, has a protective effect on cerebral multi-infarct dementia in rats. The multi-infarct dementia model rats were prepared by injecting man-made micro-thrombi into the right hemisphere. The administration groups were treated once daily with 30, 60 and 120 mg/kg Nicotiflorin (i.g.) from 5 days before ischemia operation to 3 days after the operation for biochemical examination, 10 days for Morris water maze study and morphological observations and 20 days for eight-arm radial maze task. 2,3,5-triphenyltetrazolium chloride (TTC) staining showed that infarct volume of each Nicotiflorin administration group was much smaller than that of vehicle-treated multi-infarct dementia group, and hematoxylin and eosin (HE) staining showed that histopathological abnormalities of each Nicotiflorin group were also much lighter than that of vehicle-treated multi-infarct dementia group. Each Nicotiflorin group showed much better spatial memory performance in Morris water maze tests and eight-arm radial maze task compared with the vehicle-treated multi-infarct dementia group, significantly attenuated the elevation of lactic acid and malondialdehyde (MDA) contents and the decrease in lactate dehydrogenase (LDH), Na(+)K(+)ATPase, Ca(2+)Mg(2+)ATPase and superoxide dismutase (SOD) activity in the brain tissue which was composed of striatum, cortex and hippocampus of the ischemia hemisphere at day 3 after ischemia operation. These results suggest that Nicotiflorin has protective effects on reducing memory dysfunction, energy metabolism failure and oxidative stress in multi-infarct dementia model rats.     

Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome

This study was multi-center, double-blind, placebo controlled, and involved random assignment of patients. It was carried out in the ambulances of general practitioners and internists. The aim of the study was to evaluate the efficacy and tolerance of vinpocetine in patients with a mild to moderate severe organic psychosyndrome caused by cerebral blood supply disorders and / or metabolic disturbance. Dosage of 5, 10 and 20 mg vinpocetine or placebo t.i.d. Were examined over a treatment period of 12 weeks with 282 patients. The study design required a programmed, standardized investigator training. In addition, a pre-study test was used to ensure correct and uniform execution of study control. The Clinical Global Impression (CGI) and the performance test SKT showed statistically significant differences between the verum groups and placebo. Self-assessment of mood and performance capability (EDS), and life satisfaction (LZ) confirmed these outcomes. The results of the Hachinski Ischaemia Scores did not permit an unequivocal classification of patients into primary degenerative and multi-infarct dementia types. The higher dosage groups experienced a greater therapeutic advantage than did the 5 mg t.i.d vinpocetine dosage group. Only a few side effects were observed.     

尼麦角林治疗血管性痴呆优于吡拉西坦

目的：比较尼麦角林与吡拉西坦对血管性痴呆的疗效。方法：８０例血管性痴呆病人随机分为２组。尼麦角林组４２例（男性２８例，女性１４例，年龄６８±ｓ７ａ），服用尼麦角林片１０ｍｇ，ｔｉｄ，治疗８ｗｋ。吡拉西坦组３８例（男性２６例，女性１２例，年龄６９±８ａ），服用吡拉西坦１．２ｇ，ｔｉｄ，治疗８ｗｋ。结果：尼麦角林组总有效率为７９％，吡拉西坦组为５５％（Ｐ＜０．０５）；记忆商数（ＭＱ）和长谷川痴呆量分（ＨＤＳ）尼麦角林组分别增值１２±１１分和７±６分，吡拉西坦组分别增值５±８分和４±４分，２组间比较Ｐ＜０．０５，未见不良反应。结论：尼麦角林治疗血管性痴呆的临床疗效显著优于吡拉西坦     

Efficacy of naftidrofuryl in patients with moderate senile dementia

In a controlled double-blind study, 78 patients with moderate senile dementia were randomly assigned to 3-months' treatment with 200 mg naftidrofuryl twice daily in slow-release form or with placebo. The patients were selected on the basis of the EACG (Echelle d'Appréciation Clinique en Gériatrie), which was also used as main criterion for confirmatory analysis of the efficacy of naftidrofuryl. A further main criterion was the SGRS (Stockton Geriatric Rating Scale). Secondary criteria examined were visual memory as tested in the Benton test, verbal memory as tested in the Rey test and numerical memory as tested in the digit-span test. The patients' concentration was tested in the Zazzo test. The tests were performed before the patients were admitted to the study and after 1 and 3-months' treatment. Confirmatory analysis of the primary criteria showed a significant treatment difference in favour of naftidrofuryl in the form of improvement in the global symptoms of senile dementia both in the EACG and in the SGRS, the scores in the naftidrofuryl group improving by 15% compared with only 5% in the placebo group. This was paralleled by a significant improvement in visual and verbal memory in the naftidrofuryl group in comparison with placebo. The naftidrofuryl patients also showed a greater improvement in concentration than the placebo group. One patient in the naftidrofuryl group suffered briefly from gastro-intestinal symptoms. There were no changes in routine laboratory parameters studied.     

塞来考昔和布洛芬治疗骨关节炎的比较

目的 :比较塞来考昔和布洛芬治疗骨关节炎的疗效及安全性。方法 :塞来考昔组 34例 ,给予塞来考昔 10 0mg ,po ,bid ;布洛芬组 32例 ,给予布洛芬 30 0mg ,po ,bid ,疗程 4wk。结果 :塞来考昔组的总有效率为 85 % ,布洛芬组为 81% (P >0 .0 5 ) ;2组不良反应发生率分别为 18%和 34% ,2组发生不良反应的病例数差异无显著性。结论 :塞来考昔能改善骨关节炎的症状和体征 ,疗效与布洛芬相近 ,在治疗骨关节炎中可作为非甾体抗炎药的有效替代药物     

依那普利单用与合用氢氯噻嗪治疗原发性高血压的比较

原发性高血压患者56例(男34,女22;年龄50±7a)采用依那普利2.5-20mg,bid,po,治疗4wk与6mo的疗效比较,两者治疗后均有显著降压疗效(P<0.01),但4wk与6mo治疗组间比较无差异(P>0.05)。副作用亦相仿。另对30例同样患者采用单用依那普利(剂量方法同前)及与氢氯噻嗪2.5-15mg,bid,po,联合治疗4wk作比较,联合用药优于单用组。